Parker Moss

Key takeaway [for me] so far from this morning’s panel on how to balance patient-centric #digitaltherapeutics with scalable profitability can be summarised by the phrase “Build and they will come”. If you build a product that is intrinsically engaging and keeps patient adherent to the programme, then the clinical outcomes will show themselves, product value can be seen, and uptake will come and with it the money. And how to make a product engaging? For Hannes Klöpper of HelloBetter , it’s about getting patients involved as much as possible in the product development, get their feedback, use it to make necessary tweaks to improve the technology . No brainer? Are DTx companies already doing this? Other insights from Marek Ostrowski of Prosoma Kamran Adle Christian Lautner LSX - partnering for Life Science eXecutives #lsxworldcongress Laura Wamprecht

56

1 Comment

AI has the power to solve pressing issues in health care, climate and the economy. Great to speak at Tony Blair Institute for Global Change's #FutureofBritain Conference yesterday. You can watch my speech here: https://bit.ly/4ddc5er

52

4 Comments

Hi LinkedInVerse, Interested to get people's thoughts on this news story? As many in the Medical Devices, Biotech and Drug Discovery sectors has noticed over the last year, funding/investments have not been released, even when promised and contracts signed. I've noticed a little upturn in roles recently, which hopefully means funding/investments are now being released, is this other people's recent experience? I wish any of the political parties were talking more specifically about this, and hopefully this think tank may make them do this. https://lnkd.in/eizJ6s9Q #Investment #MedicalDevices #Biotech #DrugDiscovery IPPR #TheInstituteforPublicPolicyResearch

2

Finally! The veil of silence can be lifted and we're able to shout about our biggest ever investment into a company we're seriously excited about... 😁 Despite the news leaking a couple days earlier (🙄) and with incorrect information (🙄x2) I can announce that Mercia Ventures are thrilled to have led the Series B investment into Semble: an integrated clinical system that's amplifying the impact of healthcare professionals across the UK and France.   We're always on the lookout for game-changing technologies that deliver big benefits to multiple stakeholders. I particularly love when that's in #healthcare: an area that touches all of our lives; is always relevant (no matter what state the economy's in); and is in dire need of improvement. Semble stood out from all the tech businesses we meet, because of the major benefits they're delivering to customer's businesses, workforces and patients. (More on this in an upcoming "Why we invested...")   Christoph Lippuner and Mikael Landau are A-grade co-founders, leading a topnotch team all driving towards the same vision. We're excited to partner with them and the others supporting Semble to achieve their ambitions. Jonathan Lerner Peter Duffy Seb Wallace Nicholas Sharp Jebran Raashed Laurent Schockmel Smedvig Ventures Salica Investments Triple Point Octopus Ventures #venturecapital #healthtech #investing #startups #health #France #UK Read the full story here: https://lnkd.in/eVh24z3z

164

19 Comments

It was great to be able to connect and share my thoughts and insight for the Connectivity Mix Ecosystem Insight for Connect: Health Tech (https://lnkd.in/eweszqZu) alongside some brilliant other #contributors. A really great example of what we should all be talking about - how we can improve #connectivity and #collaboration amongst ourselves and #ecosystems to the benefit of not just ourselves, but the UK as a whole. The paper has just been launched and can be read here: https://lnkd.in/eP4ptRUr. #ConnectivityMix #JoinTheDots.

35

4 Comments

The BMJ published a commentary on how the NHS should use health data more effectively on November 14, 2024. (Unlocking NHS data requires public trust Cori Crider, Jess Morley, Katie Bramall-Stainer. 387:doi 10.1136/bmj.q2494) This is an area of concern for me, and my forthcoming book, Medical Genetics and Law: An International Perspective, deals with the issues at some length, including the coverage of cybercrime against medical records worldwide. I responded to the Commentary. Unlocking NHS data requires public trust | The BMJ

3

Another fantastic #LondonBio meet up, thanks to Yasmin Siraj, Alex Brunicki & Jack O'Meara and the rest of the team for putting it on. This time the theme was on my favourite topic in the market, AI in Biotech. Key highlights for me: Always great to hear from Patrick Schwab - insightful discussions around opportunites in #datacapture and the importance of even if you’ve got the best candidates in the world, without the right tools and process to capture the data and validate successes you’re going to struggle - particuar focus here on Parkinsons and other Neuroscience areas. Point to the network - if you’re a Founder working on something in this area, Pharma is interested in hearing about it! Nan Li from Dimension gave some positive reflections on what we’re doing over in Europe is working, although we might be a little more constrained on capital than our friends over the pond, given the market dynamics and funding starting to inch towards a level(er) playing field, Founders in Europe/UK know how to make their capital work for them. I’ve found a big topic for discussion and future planning is around commercialisation of platform biotech/TechBio. What do pharma want, do they simply want to pick off promising assets, collab, recieve tools, data plays etc. from new co's. It’s still a tough one for BD professionals to properly encapsulate value in a new to market platorm and get a decent deal with a Pharma. However, it’s super promising to see these starting to come through given Ochre Bio new BI deal! On the flip side for Founders, there was a point made of not overlooking the advantage of getting a big Pharma in, and trying to go at it alone. They have the resources, clinical and commercial engine to drive forward early stage drug discovery, so worth being open to business models. M&A outlook is still on the quieter side in TechBio, with Pharma interested in watching and waiting, even if that means a more expensive purchase price, it’s worth it for them, whilst getting the occasional promising asset along the way. Always good to hear from Laksh Aithani at CHARM Therapeutics as another example of the UK's ecosystem building tech enabled drug discovery organisations - exciting news of clinical entry on the horizon. Overall market outlook is super promising, with Nan & Jack's view over the next twenty years, the historic, steadfast top 20 pharma will have a shake up with some new powerhouses coming through. Off the back of this weeks $1b funded Xaira Therapeutics, it certainly looks like the industry is continuing to crank up the heat! #techinbio #platformbiotech

93

1 Comment

I see a lot of health tech, but what looks super interesting here to me is the co-location of a software startup physically IN a GP practice. Not only reminiscent of my pop up immersion studios, but also a new angle through the conversations in community engagement and coproduction. Proximity is a form of power. #healthcareinnovation #design #immersion

3

2 Comments

Our Future Is Biotech - A guide to how a tech revolution is changing our lives and our health for the better. 💭📗 This book was released last week, authored by the fantastic Andrew Craig I listened to the book via Audible over the weekend, 9 hours in total & it's worth every minute. The book focuses on how the Biotech and related industries such as Healthcare/Digital Healthcare will have a positive impact on us all in the future. Biotech companies are solving our most intractable problems such as cancer, dementia, obesity, mental health conditions, diabetes and elderly care. Biotech means we can all live better, safer, happier, healthier & longer lives. Technology has revolutionized the world we live in over the last century, Biotech is next. This is probably the best audiobook I've ever listened to. Give it a go, thoughts & feedback welcome 😆 #biotech #machinelearning #artificialintelligence #ourfutureisbiotech

32

3 Comments

It was great to see news coming out of the Oxford Nanopore Technologies team last week at their 10th annual customer conference, London Calling. From a commercial point of view, it was encouraging that LC24 featured a ‘clinical and biopharma’ day for the first time. Gordon Sanghera, set out the many commercial partnerships through which ONT is seeking to unlock high potential applied sequencing markets, and various customers cited the more valuable insights being delivered by nanopore sequencing compared to existing technologies. Dr Danny Miller (paediatric physician) called long-read sequencing the ‘future of clinical genetic testing’. He spoke eloquently about the power to change lives, reducing what can be a lifetime of genetic tests to weeks or days with the richer data that ONT enables. Dr Miller said that even if the cost of other analyses fell to $0 he would still generate long read sequencing data to characterise rare disease in children and drive clinical decisions. While LC24 featured the usual level of tech improvements, such as the next gen ‘Transformer’ AI-driven data analysis, customers frequently cited ONT’s current technical performance as more than sufficient for their needs. This included the CDC presenter who said they plan to introduce ONT sequencing to their gold standard with its current accuracy and performance. Most of ONT’s current customers are researchers. However, longer term, the real prize is in the ‘applied markets’ so it was great to see an overview of the pathway for their products through to future, regulated in-vitro diagnostics. In the near term, the “Q line” products will support users in environments conducting routine testing, and the ONT’s ISO1345 GridION (expected in 2025) was attracting interest for clinical applications in infectious disease, cancer and human genetics. While the largest addressable market long term is cancer, infectious disease is also substantial and seems to have a lot of traction. It’s an area where nanopore-based sequencing is mature as well as giving the market advantages of speed and suitability for any setting. I was particularly inspired by the work happening here in London at Guy’s and St Thomas Hospital in respiratory metagenomics, a combination of better management of infections and an early warning system for potential emerging pathogens. And, on the cancer front, in Amsterdam’s paediatric oncology unit, who are using 45-minute sequencing workflows to guide the surgeon’s strategy live during brain surgery! The conference was as inspiring as always, both technically and commercially, and a reminder of the importance of the IP Group plc mission to evolve the power of science for a better future. #nanoporeconf #backinginnovation

55

1 Comment

Hmmm. How about an LLM for designing trials that patients are more likely to be eligible for, want to participate in, and still generate commercially useful results? The issue isn't patient matching - the ecosystem is not flush with a wide range of studies and a wide range of patients, each seeking to find each other in the darkness. Despite the large number of "studies" on CT.gov, there are only a few studies running for NCEs in most conditions - often with almost identical inclusion/exclusion criteria that are only relevant to a small fraction of patients. On the patient side, one is either happy enough with their treatment outcomes - and has little knowledge of or interest in clinical trials without the nudge of their doctor, or one has a rare disease or serious stage cancer... In which case you are quite familiar with the trials available, and - often - have found yourself to be ineligible.. I'm sorry to be blunt! Change the game. Use technology to solve the real problem - which is far upstream from helping "patients in need" match with a study. Create study designs that offer more options to more, real patients. How many people reading this post have been handed a protocol that had known feasibility challenges from the start - and that could have been addressed much better by protocol changes vs more countries, sites and patients?

12

Today, we’re kicking off an exciting two days in London with 250 incredible new colleagues from Exscientia and more than 50 longstanding Recursion leaders and ‘trail guides’ as we come together to chart the next chapter of TechBio. This is more than just a meeting—it’s the start of a shared journey to redefine how technology and biology converge to transform lives. Over the next two days, we’ll dive deep into what unites us and where we’re headed. Here’s a glimpse of what’s ahead: 🔹 Reflecting on the power of shared culture and exploring how our combined strengths will drive innovation. 🔹 Thought-provoking sessions on the evolution of our operating system, patient impact, and multi-dimensional biology—key pillars of the future of TechBio. 🔹 Hands-on breakout sessions like “My Why,” where we’ll connect on a personal level to discover the passion that fuels each of us. 🔹 Collaborative discussions with HR and IT to ensure we build the infrastructure to innovate at scale. 🔹 Fun and creative activities to celebrate this unique milestone—because building the future of TechBio and working this hard should also be fun! TechBio is not just about combining biology and technology; it’s about leveraging data, systems, and innovation to tackle the hardest problems in healthcare, from drug discovery to patient outcomes. As we unite our teams and visions, we’re poised to accelerate this revolution and set the standard for what’s possible in this field. I’m excited about the conversations we’ll have, the ideas we’ll generate, and the bonds we’ll form over these two days. Together, we are laying the foundation for an extraordinary 2025 and beyond. Let’s make this moment count. #TechBio #Innovation #Collaboration #FutureOfHealthcare

271

3 Comments

The NHS have recognised systemic failures (Lord Darzi's review) and are reforming for the future with three macro shifts identified: A shift from treatment to prevention. A shift from hospitals to primary and community care. A shift from analogue to digital, with a focus on innovation. They note that data & digital are a key foundation to a tech integrated healh system. https://lnkd.in/gtVRdNAM

3

The first few patients are always the most critical in the life cycle of a cell therapy product. One gets a fundamental understanding about the product's safety profile, the surgeon's ability to deliver it without major side effects and finally and most importantly, how the cells interact with the diseased retina. The first principles knowledge arrived at over the last few weeks has enhanced our confidence in the eventual ability of this product to potentially transform patient lives. Download the full press release including what our Principal Investigators think from the link below !

154

46 Comments

Thank you Sophie Drinkwater, Senior Scientist in Microbiology at AstraZeneca and Jon Kallay, Senior Scientific Portfolio Specialist, Charles River Laboratories Microbial Solutions for presenting in yesterday's live webinar titled Building the House of Rapid Sterility – A Successful Platform Approach to introducing Rapid Methods If you missed this webinar, you can still watch it on demand https://lnkd.in/ezjr4M_K #Sterility #SterilityTesting #Validation #PharmaceuticalMicrobiology #RapidMicrobiologicalMethods #Biopharma #QualityControl #ATPBioluminescence #CFU #microorganismColonyForming #ATP #subculturing #solator #DirectInoculation #FiltrationTests #Isolator #PharmaceuticalProcess #Bioprocessing #ProcessValidation #CellTherapies #GeneTherapies #ATPBioluminescence #RapidSterility #ClosedFiltrationSystems #SterilityTestPump #ParenteralProducts #Pharmaceuticals #QC

1

An important message of support for UK life sciences, as it's named as one of eight key growth sectors in the Government's new Industrial Strategy. As set out in today's green paper, the UK’s life sciences sector "offers unparalleled opportunities for future economic growth, propelled by new discoveries, data availability, AI, groundbreaking treatments, personalised healthcare, and innovative manufacturing processes." There's now a significant window of opportunity for businesses to help shape the industrial strategy by working in partnership with Government. https://lnkd.in/e2CEQK99

7

This is an excellent piece of work from Georgia, linking real world oncology data, chemotherapy regimes and outcomes for 15000 patients from #NDRS National cancer register in England. The inference of disease free survival is a significant step in large scale datasets. If you are in Basel, definitely one to check out and really exemplifing the novel thought leadership in oncology at Genomics England Matthew Brown Richard Scott Emma McCargow #cancer #realworlddata #bigdata #ndrs #ncras

35